Summary
Pfizer Inc. (PFE) filed an 8-K on February 8, 2022, reporting its fourth-quarter and full-year 2021 financial results. The primary purpose of this filing is to furnish a press release that details these financial outcomes. Investors should note that the information provided in this filing, while containing important financial data, is furnished and not deemed 'filed' under the Securities Exchange Act of 1934, meaning it does not carry the same legal implications as a formally filed document unless explicitly incorporated into future filings. The press release, as referenced in the 8-K, contains the company's performance for the fourth quarter and the entirety of the 2021 fiscal year. While the specific financial figures are not detailed within the 8-K text itself, the filing indicates that these results are now publicly available and serve as the basis for investor understanding of Pfizer's recent performance and financial condition.
Key Highlights
- 1Pfizer announced its Q4 and full-year 2021 financial results via a press release furnished with the 8-K.
- 2The filing date is February 8, 2022, with the event date of the press release also being February 7, 2022.
- 3The press release (Exhibit 99) contains the detailed financial results for the reported periods.
- 4Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
- 5The 8-K includes the Exhibit Index, listing the press release and the cover page interactive data file.